The Business (Tables)

3 Months Ended

Mar. 31, 2017

The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates as listed below. All intercompany activities have been eliminated in consolidation.



Entity	Percentage of Ownership	Location
Caladrius Biosciences, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America
Athelos Corporation (1)	98.4%	United States of America
PCT, LLC, a Caladrius Company (2)	80.1%	United States of America
NeoStem Family Storage, LLC (2)	80.1%	United States of America
PCT Allendale, LLC (2)	80.1%	United States of America

_________________________________________________________________

(1) As of March 31, 2017, Becton Dickinson's ownership interest was 1.6%.

(2) As of March 31, 2017, Hitachi's ownership interest was 19.9% (see Note 3).